Understand the source comparison
Research-Grade Peptides by Recovery Phase: Acute vs Chronic PCS
Timing determines which peptides matter. Acute-phase interventions (0–14 days post-injury) target excitotoxicity and blood-brain barrier stabilisation. Chronic-phase protocols (2+ months post-injury) focus on neuroplasticity, dendritic remodelling, and persist
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Timing determines which peptides matter. Acute-phase interventions (0–14 days post-injury) target excitotoxicity and blood-brain barrier stabilisation. Chronic-phase protocols (2+ months post-injury) focus on neuroplasticity, dendritic remodelling, and persistent inflammation. Using neurogenesis peptides in the acute inflammatory phase achieves little. Neuroplasticity compounds work once the excitotoxic window closes.
- Acute Phase (0–14 Days): Cerebrolysin and Thymalin dominate here. Cerebrolysin's neuroprotective effect peaks when administered within 72 hours of injury. The window before irreversible apoptotic cascades complete. Standard research protocol: 10–30mL IV daily for 10–21 days. Thymalin subcutaneous administration (5–10mg daily for 7–10 days) modulates cytokine storms that compound secondary damage.
- Subacute Phase (2–8 Weeks): P21, a ciliary neurotrophic factor (CNTF) mimetic, shows peak efficacy during this window. CNTF promotes oligodendrocyte survival and axonal remyelination. The repair processes that restore conduction velocity in damaged white matter tracts. Rodent studies using P21 analogs post-TBI showed 35% improvement in Morris water maze performance vs vehicle controls when administered during weeks 2–6.
- Chronic Phase (2+ Months): Neuroplasticity compounds like Dihexa and P21 address persistent cognitive deficits. Chronic PCS involves reduced hippocampal neurogenesis, impaired long-term potentiation (LTP), and decreased dendritic spine density. All reversible with sustained BDNF upregulation. Dihexa's potency is seven orders of magnitude greater than BDNF itself in in vitro synaptogenesis assays, making it the leading candidate for chronic cognitive rehabilitation.
- Blood-brain barrier stabilisation is the overlooked fourth mechanism. Post-concussion BBB permeability persists for weeks, allowing peripheral cytokines to infiltrate CNS tissue and sustain neuroinflammation. MK-677 (ibutamoren), a growth hormone secretagogue, upregulates IGF-1. Which restores tight junction protein expression in cerebral endothelial cells. A 2020 study in Neuroscience Letters showed MK-677 administration reduced Evans blue dye extravasation (a BBB permeability marker) by 40% in rodent TBI models.